Sep 25, 2024 4:05pm EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
Jul 22, 2024 7:00am EDT Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
May 15, 2024 1:05pm EDT Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
Feb 13, 2024 4:05pm EST Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Nov 14, 2023 4:05pm EST Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
Oct 06, 2023 4:06pm EDT Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors
Sep 20, 2023 4:29pm EDT Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
Aug 30, 2023 8:00am EDT Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences
Aug 21, 2023 8:00am EDT Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension